Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease

[en] Amyloid plaques (AP) represent one of the main molecular hallmarks of Alzheimer's disease (AD). In order to develop new AP-specific contrast agents for AD molecular imaging, the phage display technology was used to identify peptides specific to amyloid-beta (A beta(42)). A random disulfide constrained heptapeptide phage display library was screened against A beta(42). After biopanning, 72 phage clones were isolated and their binding affinity to A beta(42) was evaluated by enzyme-linked immunosorbent assay (ELISA). The final library was enriched in two peptide sequences. The K(d) of candidate phage clones for binding to A beta(42) are in the picomolar range. The binding affinity for A beta(42) of two selected peptides was confirmed by ELISA, and the specific interaction with AP was validated by immunohistochemistry on brain sections. The preliminary MRI in vivo study, which was performed with a peptide functionalized contrast agent on AD transgenic mouse, showed encouraging results. To conclude, low molecular weight peptides presenting a specific affinity for A beta(42) were identified by phage display. As specific carriers, they have a real potential for molecular imaging of AD thanks to AP binding.

Disciplines :

Radiology, nuclear medicine & imaging
Biotechnology

Author, co-author :

Larbanoix, Lionel

Burtea, Carmen ; Université de Mons > Faculté de Médecine et de Pharmacie > Chimie générale, organique et biomédicale

Laurent, Sophie ; Université de Mons > Faculté de Médecine et de Pharmacie > Chimie générale, organique et biomédicale

Van Leuven, Fred

Toubeau, Gérard

Vander Elst, Luce ; Université de Mons > Faculté de Médecine et de Pharmacie > Chimie générale, organique et biomédicale

Muller, Robert ; Université de Mons > Faculté de Médecine et de Pharmacie > Chimie générale, organique et biomédicale

Language :

English

Title :

Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease

Publication date :

31 October 2010

Journal title :

Neurobiology of Aging

ISSN :

0197-4580

Publisher :

Elsevier, Netherlands

Volume :

Issue :

Pages :

1679-89

Peer reviewed :

Peer Reviewed verified by ORBi

Research unit :

M108 - Chimie générale, organique et biomédicale
M118 - Histologie

Research institute :

R550 - Institut des Sciences et Technologies de la Santé

Available on ORBi UMONS :

since 29 October 2015

Statistics

Number of views

2 (0 by UMONS)

Number of downloads

0 (0 by UMONS)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Benveniste H., Einstein G., Kim K.R., Hulette C., Johnson A. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(24):14079-14084.
Borthakur A., Gur T., Wheaton A.J., Corbo M., Trojanowski J.Q., Lee V.M.-Y., Reddy R. In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. MRI 2006, 24:1011-1017.
Boutry S., Burtea C., Laurent S., Toubeau G., Vander Elst L., Muller R.N. Magnetic resonance imaging of inflammation with a specific selectin-targeted contrast agent. Magn. Reson. Med. 2005, 53(4):800-807.
Brass S.D., Chen N.K., Mulkern R.V., Bakshi R. Magnetic resonance imaging of iron deposition in neurological disorders. Top. Magn. Reson. Imaging 2006, 17(1):31-40.
Bryant L.H., Brechbiel M.W., Wu C.C., Bulte J.W.M., Herynek V., Frank J.A. Synthesis and relaxometry of high-generation (G=5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates. J. Magn. Reson. Imaging 1999, 9(2):348-352.
Burtea C., Laurent S., Murariu O., Rattat D., Toubeau G., Verbruggen A., Vansthertem D., Vander E.L., Muller R.N. Molecular imaging of αvβ3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc. Res. 2008, 78(1):148-157.
Clackson T., Lowman H.B. Phage Display: Practical Approach 2004, Oxford University Press Inc., New York.
Dhenain M., El Tannir El T.N., Wu T.D., Guegan M., Volk A., Quintana C., Delatour B. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol. Aging 2007, 10.1016/j.neurobiolaging.2007.05.018.
Haataja L., Gurlo T., Huang C.J., Bulter P.C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 2008, 29(3):303-316.
Hartmann T., Bieger S.C., Bruhl B., Tienari P.J., Ida N., Allsop D., Roberts G.W., Masters C.L., Dotti C.G., Unsicker K., Beyreuther K. Distinct sites of intracellular production for Alzheimer's disease A beta 40/42 amyloid peptides. Nat. Med. 1997, 3(9):1016-1020.
Higuchi M., Iwata N., Matsuba Y., Sato K., Sasamoto K., Saido T.C. F-19 and H-1 MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 2005, 8(4):527-533.
Huang X.D., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E., Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E., Bush A.I. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999, 38(24):7609-7616.
Iversen L.L., Mortishiresmith R.J., Pollack S.J., Shearman M.S. The toxicity in-vitro of beta-amyloid protein. Biochem. J. 1995, 311:1-16.
Jack C.R., Garwood M., Wengenack T.M., Borowski B., Curran G.L., Lin J., Adriany G., Grohn I.H.J., Grimm R., Poduslo J.F. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 2004, 52(6):1263-1271.
Jagust W., Reed B., Mungas D., Ellis W., Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007, 69(9):871-877.
Kang C.K., Jayasinha V., Martin P.T. Identification of peptides that specifically bind A beta(1-40) amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display. Neurobiol. Dis. 2003, 14(1):146-156.
Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47(1):65-81.
Lee S.P., Falangola M.F., Nixon R.A., Duff K., Helpern J.A. Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn. Reson. Med. 2004, 52(3):538-544.
Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(s1):s46-s50.
Orner B.P., Liu L., Murphy R.M., Kiessling L.L. Phage display affords peptides that modulate beta-amyloid aggregation. J. Am. Chem. Soc. 2006, 128(36):11882-11889.
Poduslo J.F., Curran G.L., Peterson J.A., McCormick D.J., Fauq A.H., Khan M.A., Wengenack T.M. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 2004, 43(20):6064-6075.
Rapoport M., Ferreira A. PD98059 prevents neurite degeneration induced by fibrillary beta-amyloid in mature hippocampal neurons. J. Neurochem. 2000, 74(1):125-133.
Rogers J., Lue L.F. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 2001, 39(5/6):333-340.
Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 1989, Cold Spring Harbor Laboratory Press, New York.
Segers J., Laumonier C., Burtea C., Laurent S., Elst L.V., Muller R.N. From phage display to magnetophage, a new tool for magnetic resonance molecular imaging. Bioconjug. Chem. 2007, 18(4):1251-1258.
Sigurdsson E.M., Wadghiri Y.Z., Mosconi L., Blind J.A., Knudsen E., Asuni A., Scholtzova H., Tsui W.H., Li Y., Sadowski M., Turnbull D.H., de Leon M.J., Wisniewski T. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging 2007, 10.1016/j.neurobiolaging.2006.12.018.
Sipe J.D. Amyloid Proteins. The Beta Sheet Conformation and Disease 2005, WILEY-VCH, New York.
Smith G.P., Petrenko V.A. Phage display. Chem. Rev. 1997, 97(2):391-410.
Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van den Haute C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R., Van Leuven F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am. J. Pathol. 2000, 157(4):1283-1298.
Vanhoutte G., Dewachter I., Borghgraef P., Van Leuven F., Van der Linden A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 2005, 53(3):607-613.
Wadghiri Y.Z., Sigurdsson E.M., Sadowski M., Elliott J.I., Li Y.S., Scholtzova H., Tang C.Y., Aguinaldo G., Pappolla M., Duff K., Wisniewski T., Turnbull D.H. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 2003, 50(2):293-302.
Weissleder R., Mahmood U. Molecular imaging. Radiology 2001, 219(2):316-333.
Wiesehan K., Buder K., Linke R.P., Patt S., Stoldt M., Unger E., Schmitt B., Bucci E., Willbold D. Selection of d-amino-acid peptides that bind to Alzheimer's disease amyloid peptide A beta(1-42) by mirror image phage display. Chembiochem 2003, 4(8):748-753.
Zhao M., Kircher M.F., Josephson L., Weissleder R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 2002, 13(4):840-844.
Zwick M.B., Shen J.Q., Scott J. Phage-displayed peptide libraries. Curr. Opin. Biotechnol. 1998, 9(4):427-436.